RetinaCME
EXPERT VIDEOCME

RetinaCME Presents Updates from Honolulu: Best of Ophthalmology Research - Long-term Management of AMD

Author(s)/Faculty: Rishi P. Singh, MD; David M. Brown, MD, FACS; Nathan C. Steinle, MD
Release Date: 5/15/2018Expiration Date: 5/14/2019
Credit Type: CMENumber of Credits: 0.75
Content Type: VideoProvider: Vindico Medical Education
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment. It is estimated that by the year 2020, AMD will develop in nearly 3 million individuals in the United States and the prevalence will continue to rise. Management of AMD has been revolutionized by the integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into treatment protocols. Unfortunately, dramatic vision gains observed at initiation of therapy are not always maintained with longer-term therapy, and as AMD is a chronic, progressive disease, patients require effective long-term treatment strategies. In this educational activity, recorded during the spring meeting in Honolulu, experts in the field review long-term intravitreal anti-VEGF treatment protocols, discuss outcomes from pinnacle clinical studies, and evaluate newer studies demonstrating visual acuity gains with long-term therapy.